The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of lapatinib (LPT) and cetuximab (CTX) in patients with CTX-sensitive solid tumors.
John F. Deeken
No relevant relationships to disclose
Hongkun Wang
No relevant relationships to disclose
Jimmy J. Hwang
No relevant relationships to disclose
John Marshall
No relevant relationships to disclose
Deepa Suresh Subramaniam
No relevant relationships to disclose
Aiwu Ruth He
No relevant relationships to disclose
Louis M. Weiner
No relevant relationships to disclose
Rosemarie A. Hardesty
No relevant relationships to disclose
Kenneth Steadman
No relevant relationships to disclose
Michael J. Pishvaian
No relevant relationships to disclose